--- title: "Amass *Core — Eight *Cores, one retrieval engine" description: "One query searches eight *Cores in parallel, from 43M+ papers to 170M+ patents, and every claim carries the ID of its source record." url: https://amass.tech/core --- # Amass *Core — Eight *Cores, one retrieval engine Amass \*Core # Eight \*Cores, one retrieval engine. One query searches biomedical and scholarly literature, trials, drugs, genes, patents, FDA and EMA documents and the live web in parallel. Every claim in the answer carries the identifier of the record it came from, such as a PMID, an NCT ID or a patent number. [Get an API key](https://platform.amass.tech/api-keys)[Book a demo](https://amass.tech/demo) Architecture ## How a query fans out and comes back cited The engine sends one plain-language query to every relevant \*Core at once, merges the results and returns one JSON response, with a citation on each claim. 8 \*Cores App MCP API Amass \*Core architecture BioMedCore ScholarCore PatentCore RegulatoryCore DrugCore TrialCore GeneCore WebCore Provenance & citations External data providers - PubMed - PMC - Crossref - USPTO - EPO - WIPO - SureChEMBL - FDA - EMA - ClinicalTrials.gov - WHO ICTRP - HGNC - Ensembl - UniProt - ChEMBL - Web Connect your own data - SharePoint - OneDrive - Google Drive - Databricks - S3 / Blob - Network drives 500M+records in the registry 1. BioMedCore43M+ 2. ScholarCore233M+ 3. PatentCore170M+ 4. DrugCore22K+ 5. TrialCore1.2M+ 6. GeneCore43K+ Plus FDA + EMA regulatory records and the live web. [Details in the platform documentation →](https://platform.amass.tech/documentation/getting-started/overview) ### BioMedCore PubMed, PMC and conference abstracts BioMedCore ## 43M+ PubMed and PMC papers plus conference abstracts - Full PubMed and PubMed Central coverage with abstracts and full text - Conference abstracts from society meeting supplements - Citation counts, journal impact metrics, and quality signals - MeSH-enriched metadata for precise filtering BioMedCore Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial [PMID 34051124](https://pubmed.ncbi.nlm.nih.gov/34051124/)Solomon SD, McMurray JJV, et al.Eur J Heart Fail, 2021doi 10.1002/ejhf.2249 ### ScholarCore Scholarly papers across all disciplines ScholarCore ## 233M+ papers and preprints across every discipline - Journal articles, preprints and proceedings papers from outside biomedicine - Cross-disciplinary reach beyond the biomedical literature - Reaches work that has not yet appeared in BioMedCore ### PatentCore Life-science patents indexed PatentCore ## 170M+ patent filings from every major office: claims, families, and cross-links to drugs and papers - 16.8M publications across every major office: US, EP, WIPO/PCT, CN, JP, KR, and more - Full-text search over title, abstract, claims, and description - CPC/IPC classifications, assignees, inventors, and four dates (priority, filing, publication, grant) - Search collapses each family to one publication, so a landscape isn't flooded with near-duplicates - 12.5M patents linked to a drug in DrugCore; citation lineage and references into BioMedCore PatentCore GLP-1 analogues and derivatives [US-8815802-B2](https://patents.google.com/patent/US8815802B2)Novo Nordisk A/Sfiled 2010-12-16granted 2014-08-26 ### RegulatoryCore FDA & EMA documents indexed RegulatoryCore ## 7K+ FDA and EMA authorizations on one schema: approvals, labels, EPARs, and designations - FDA application records, drug labels, review documents, and approval letters - EMA EPARs, assessment reports, and SmPCs: European authorizations in full - Unified authorization status, plus Breakthrough, PRIME, and Accelerated Approval designations - Orphan tracking, cross-linked to the drug each authorization covers in DrugCore RegulatoryCore Kisunla (donanemab-azbt), Alzheimer’s disease [BLA 761248](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248)FDAEli Lillyapproved 2024-07-02 ### DrugCore ChEMBL drugs & molecules indexed DrugCore ## 22K+ harmonized drugs and molecules: modality, clinical stage, and structure - ChEMBL-derived drug records with names, trade names, and synonyms, harmonized - Chemical structures with InChIKey and SMILES, plus modality classification - Highest clinical stage reached, from preclinical through approval - Parent/child relationships, cross-linked to trials, literature, and regulatory records DrugCore Semaglutide [CHEMBL2108724](https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2108724)ProteinApprovedOzempic · Wegovy · Rybelsus ### TrialCore Clinical trials indexed TrialCore ## 1.2M+ trials from ClinicalTrials.gov and international registries: status, endpoints, sponsor - ClinicalTrials.gov and international registries (590K+ and 610K+), with AI-enhanced search - Enrollment status, endpoints, and sponsor intelligence - Phase, indication, and comparator filtering - Trial-to-publication linking for evidence completeness TrialCore ESSENCE: semaglutide in non-alcoholic steatohepatitis [NCT04822181](https://clinicaltrials.gov/study/NCT04822181)Phase 3Active, not recruitingNovo Nordisk1,205 enrolled ### GeneCore Human genes indexed GeneCore ## 43K+ harmonized human genes, with druggability and constraint, cross-linked to DrugCore - HGNC, NCBI, UniProt, and Ensembl, harmonized on one schema - Druggability and tractability assessments, by modality and clinical precedent - Genetic constraint via gnomAD v4.0: pLI and LOEUF loss-of-function scores - Cellular essentiality from CRISPR dependency screens: genes required for cell survival - Each gene cross-links to the drugs that target it in DrugCore, and through those drugs to trials and papers GeneCore KRAS, KRas proto-oncogene, GTPase [HGNC:6407](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407)12p12.1UniProt P01116small molecule: approved drug ### WebCore Real-time web sources WebCore ## Real-time web sources, including company sites, press releases and conference news - Company sites, press releases and conference news - Current events that no fixed corpus has indexed yet - Cited the same way as every other source Capabilities ## What you get back from every query - ### Cited answers Citations sit inline, next to the claim they support. - ### Unified retrieval One query reaches all 8 \*Cores in parallel, and the results come back merged. - ### Agent execution Agents plan multi-step research, iterate on intermediate results and return structured output. - ### Enterprise controls Workspace roles, EU hosting, and single-tenant or bring-your-own-cloud deployment for regulated environments. - ### API and MCP access The REST API for your own code, the MCP for Claude, ChatGPT, Claude Code and Codex. Both serve six of the eight \*Cores. - ### Structured outputs Tables, JSON and tagged extracts your code can parse, as well as prose. ## Query the engine from your terminal The REST API serves six of the \*Cores. One request with your key returns typed JSON records with their source identifiers. [Get an API key](https://platform.amass.tech/api-keys)[Book a demo](https://amass.tech/demo) Data No training on your data Hosting EU-hosted, enterprise Isolation Tenant-isolated by architecture Certification ISO 27001, SOC 2, NIS2: in motion